Mission and Money Clash in Nonprofit Hospitals’ Venture Capital Ambitions

Nonprofit hospital systems have increasingly positioned themselves as venture capitalists, seeking diversified revenue streams and innovation-driven competitive advantages. However, a fundamental tension persists between fiduciary duty to charitable mission and financial returns optimization. Nonprofit hospitals' combined investment portfolios—encompassing stocks, hedge funds, private equity, and venture capital vehicles—reached $283 billion, representing significant capital reallocation from core operations. This growth trajectory accelerated substantially: institutional holdings expanded from $43 billion in 2010 to $108 billion by 2021, reflecting systemic shift toward alternative asset classes.

Cone Health's experience with Wellsmith illustrates the practical constraints of hospital-backed venture investing. The North Carolina-based nonprofit system committed $12 million to develop a smartphone platform enabling diabetes self-management, generating promising clinical outcomes including user weight reduction and improved glycemic control. Despite clinical validation, Cone management determined the venture was economically unviable due to competitive market saturation in digital health applications. Critically, the shutdown decision was not driven by clinical efficacy concerns but by inability to generate meaningful financial returns or secure an acquisition or licensing arrangement. Wellsmith's CEO Jeanne Teshler observed that while Cone Health provided essential funding, the health system could not function as a customer—a structural limitation that prevented venture viability despite clinical merit.

Systemic misalignment between mission rhetoric and capital allocation patterns undermines the stated rationale for hospital venture investment. Only $19 billion (7%) of nonprofit hospitals' total investment portfolios are designated as principally devoted to nonprofit healthcare missions, suggesting that the majority of venture capital deployment prioritizes financial returns over mission-aligned outcomes. This disparity raises governance questions regarding whether hospital boards adequately balance philanthropic mandates with fiduciary return obligations.

Additional execution challenges plague hospital-backed venture portfolios. Internal adoption failures occur when hospital systems' own clinicians reject sponsored innovations due to skepticism or established workflows, creating a critical customer-acquisition barrier. Furthermore, venture investments exhibit cyclical vulnerability: budgetary pressures and corporate reorganizations frequently force portfolio reassessment and premature exits incompatible with venture-stage capital requirements. These dynamics suggest hospital systems may lack operational expertise, governance structures, and risk tolerance required for successful venture capital deployment at institutional scale.